HR-1432-119
Referred to the House Committee on the Judiciary.
Sponsored by Chip Roy (R-TX)
What it does
The bill would prohibit any federal law, including named provisions of the Public Health Service Act (the PREP Act and the National Childhood Vaccine Injury Act), from making a COVID-19 vaccine manufacturer immune from suit or liability, or from limiting that liability, for claims of loss tied to the vaccine's administration or use. It would let people sue even if they sought or received payment from the Countermeasures Injury Compensation Program or the National Vaccine Injury Compensation Program, and would not bar them from using those programs. It would apply to vaccinations given before, on, or after enactment.
Who benefits
People who say they were injured by a COVID-19 vaccine and who could gain a path to court claims against manufacturers. Plaintiffs' attorneys who could bring such cases. Claimants who found the federal compensation programs slow or limited in payouts and who could seek damages in court instead. Families of people who died after vaccination and who allege a link.
Who is hurt
COVID-19 vaccine manufacturers, which would face litigation exposure and possible damages for past and future doses. Their insurers and shareholders, who could bear litigation costs and liability. Federal and state public health programs that may find it harder to secure manufacturers for future emergency vaccines. Courts, which could see a surge of mass-injury filings, and defendants facing claims that science may not support.
Supporters argue
Supporters argue that people harmed by a product that the government encouraged or required deserve access to courts, and that liability shields remove manufacturers' incentive to maximize safety. They contend the federal compensation programs have paid few claims and cap benefits, so a civil option, preserved alongside those programs, offers injured people a real remedy.
Opponents argue
Opponents argue that liability protections were set up so manufacturers would develop vaccines quickly in an emergency, and removing them could discourage future vaccine development and supply. They contend the compensation programs exist to pay valid claims without lengthy trials, and that retroactive liability for doses given under existing law raises fairness concerns and could create heavy litigation costs.
Constitutional context
Congress may regulate civil liability for products in interstate commerce under the Commerce Clause and may withdraw statutory immunities it created. The retroactive application raises Due Process Clause questions about upsetting settled expectations; the closest anchor is Landgraf v. USI Film Products (1994), which sets a presumption against retroactive statutes, though Congress may overcome it with clear language as this bill does, and economic legislation usually survives due process review under cases like Pension Benefit Guaranty Corp. v. R.A. Gray (1984).
Checks and balances
Congress would narrow its earlier delegation of immunity to the executive's emergency declarations, shifting authority to courts and juries, with judicial review of retroactivity and the executive branch retaining enforcement roles in the compensation programs.
Historical precedent
The National Childhood Vaccine Injury Act of 1986 and the PREP Act of 2005 created the liability limits and compensation programs this bill targets, and Bruesewitz v. Wyeth (2011) upheld the 1986 Act's preemption of certain vaccine design-defect claims.